Olio Labs
YC S23Founded 2023 · 5 employees · 5 known investors
Olio Labs develops drug combination therapies using machine learning to identify treatments that target multiple interacting proteins simultaneously, with initial candidates focused on obesity treatment. The company aims to create pharmaceutical solutions that achieve greater efficacy and lower side effect profiles than existing single-target medications.
Founders & leadership· Y Combinator alumni (S23)
Olio Labs was founded in 2023 by David Tingley and Tom Roseberry.
DT
David Tingleyin𝕏FounderDavid Tingley holds a PhD in Neuroscience from New York University and completed postdoctoral research at Harvard Medical School. He has over 13 years of experience in systems neuroscience and biology, with published research on the relationship between neural oscillations and metabolic processes.
TR
Tom Roseberryin𝕏Co-Founder & CTOTom Roseberry has 15+ years of experience in aerospace, neural interface development, and drug discovery. He previously served as VP of Engineering at Loyal overseeing computational biology and drug development teams, and at Neuralink led a group developing neural interface technology.
Investors · 5
Competitors · 5
by search overlap
Olio4 shared keywordsOlio provides care coordination technology for post-acute and behavioral health organizations, automatically connecting care teams across SNFs, behavioral health providers, payers, health systems, home health, and hospice to improve outcomes and reduce costs.
Olioapp4 shared keywordsOlio is a mobile app that lets neighbours and local shops give away or sell surplus food and household items, connecting people nearby to reduce waste and access free items. It also runs a volunteer program where "Food Waste Heroes" collect surplus food from local businesses to redistribute in their community.
Elio4 shared keywordsElio develops adaptive sensors that enable AI systems to dynamically select information at variable resolutions and dimensions, giving machine intelligence direct perception capabilities for physical world applications.
Aulos Bioscience3 shared keywordsAulos develops an immune-activating monoclonal antibody therapeutic for cancer, using AI to design an antibody targeting the IL-2 portion that interacts with the CD25 receptor to shift IL-2 activity toward immune activation. Its lead investigational candidate, imneskibart, is in a Phase 1/2 clinical trial for solid tumor cancers including melanoma and renal cell carcinoma.
Altos Labs3 shared keywordsAltos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.
Companies competing with Olio Labs for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Olio Labs do?
- Olio Labs develops drug combination therapies using machine learning to identify treatments that target multiple interacting proteins simultaneously, with initial candidates focused on obesity treatment. The company aims to create pharmaceutical solutions that achieve greater efficacy and lower side effect profiles than existing single-target medications.
- Who founded Olio Labs?
- Olio Labs was founded by David Tingley, Tom Roseberry in 2023.
- Who are Olio Labs's investors?
- Olio Labs's investors include Overwater Ventures Llc, SciFounders, Scrum Ventures, Y Combinator, ZAKA VC.